ALMR.Y Stock Overview

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. More details

ALMR.Y fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	1/6

Rewards

Trading at 78.5% below our estimate of its fair value

Earnings are forecast to grow 54.15% per year

Risk Analysis

Dividend of 2.17% is not well covered by earnings or free cash flows

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Almirall, S.A. Competitors

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$2.1b

Amneal Pharmaceuticals

NasdaqGS:AMRX

US$2.4b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$1.8b

Bausch Health Companies

NYSE:BHC

US$2.8b

Price History & Performance

Summary of share price highs, lows and changes for Almirall
Historical stock prices
Current Share Price	€9.90
52 Week High	€10.62
52 Week Low	€8.81
Beta	0.36
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.12%

Recent updates

Shareholder Returns

	ALMR.Y	US Pharmaceuticals	US Market
7D	0%	-1.9%	-1.1%
1Y	n/a	6.5%	22.4%

Return vs Industry: Insufficient data to determine how ALMR.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ALMR.Y performed against the US Market.

Price Volatility

Is ALMR.Y's price volatile compared to industry and market?
ALMR.Y volatility
ALMR.Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ALMR.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ALMR.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1943	1,996	Carlos Gallardo Piqué	www.almirall.com

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
ALMR.Y fundamental statistics
Market cap	US$1.88b
Earnings (TTM)	-US$46.73m
Revenue (TTM)	US$992.91m

1.9x

P/S Ratio

-40.3x

P/E Ratio

Is ALMR.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALMR.Y income statement (TTM)
Revenue	€953.49m
Cost of Revenue	€255.10m
Gross Profit	€698.39m
Other Expenses	€743.26m
Earnings	-€44.87m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.21
Gross Margin	73.25%
Net Profit Margin	-4.71%
Debt/Equity Ratio	23.6%

How did ALMR.Y perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

-107%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/23 05:30
End of Day Share Price	2024/08/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Almirall, S.A. is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elena Fernández	Ahorro Corporación
Guilherme Sampaio	Banco BPI, S.A.
Álvaro Arístegui Echevarría	Banco de Madrid S.A.U.